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†Deṕartement de Chimie, Ecole Normale Supeŕieure, 24 rue Lhomond, 75231 Paris cedex 05, France
‡Universite ́ Pierre et Marie Curie, Paris, France
§UMR 7203, Laboratoire des BioMolećules, CNRS/UPMC/ENS, Paris, France
∥Institut Curie, 91405 Orsay, France
⊥INSERM U759, 91405 Orsay, France
#UMR 8221, Laboratoire de Biologie Structurale et Radiobiologie, iBiTec-S, CEA, 91191 Gif-sur-Yvette, France
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ABSTRACT: The optimum conditions for the formation of
plate-like and urchin-like microcrystals of biomolecules and
their transfer to rotors for solid-state NMR spectroscopy
depend on a variety of factors, of which minimizing the
manipulation of the microcrystals and storing the sample for
several months at 277 K (4 °C) play an important role. Three
biological systems were investigated: Hen Egg-White (HEW)
lysozyme (129 residues), the lengthened C-terminal domain
(LCter) of Human centrin 2 (89 residues), and the complex
between the C-terminal domain (Cter) of Human centrin 2 (79 residues) and the P17-XPC peptide (17 residues).
■ INTRODUCTION
Microcrystals of proteins that are suitable for solid-state NMR
can be produced in considerable amounts and much more
quickly than single crystals for X-ray diﬀraction. Microcrystals
are not only relevant for the delivery of biopharmaceuticals1 but
also for the characterization of biophysical properties of
proteins such as local motions that are believed to be pertinent
for their function. Several methods have been developed to
study proteins in microcrystalline form, including diﬀerential
scanning calorimetry,2 infrared spectroscopy combined with
one or two-dimensional Fourier transformation,3−6 mass
spectrometry,7,8 electron microscopy,2,9 X-ray powder diﬀrac-
tion,9,10 atomic force microscopy,11,12 and solid-state nuclear
magnetic resonance (NMR) spectroscopy for site-speciﬁc
investigations of protein structure13 and dynamics.14 Besides,
solid-state NMR (ssNMR) is so far the only technique capable
of getting structural information and conformational dynamics
of membrane proteins, amyloid ﬁbrils, and other noncrystalline
systems.15,16 The past decade has witnessed considerable
instrumental and methodological progress in solid-state
NMR. However, to date, only a handful of microcrystalline
proteins prepared by dialysis, precipitation, vapor diﬀusion, or
the batch method have been studied by solid-state NMR.17−28
This is in large part owing to the fact that obtaining
microcrystals suitable for this technique is not easily achieved
in routine.
Solid-state NMR allows elucidating structural features of
biological samples in a manner that is complementary to X-ray
crystallography. In contrast to solution-state NMR, there are no
limitations imposed by the solubility, and NMR spectra are not
aﬀected by the molecular weight. In addition, the use of spin-
relaxation experiments on microcrystalline proteins opens new
avenues for the investigation of internal dynamics on time
scales that extend beyond the overall tumbling time of the
molecule. In solution, the overall molecular tumbling of the
molecule masks such internal motions. However, preparing
samples of suﬃcient quality and quantity for solid-state NMR
turns out to be a tremendously diﬃcult task. Protein samples
need to fulﬁll various requirements for solid-state NMR, which
needs large quantities (on the order of 5 mg), homogeneity,
low-salt concentration, adequate morphology of the micro-
crystals, and stability with respect to time and temperature
variations. Moreover, fast and reproducible preparation
protocols are desirable. Small rotors (i.e., 1.3 and 2.5 mm
outer diameter) for fast and ultrafast spinning MAS experi-
ments require robust ﬁlling methods. Using small diameter
rotors enables faster sample spinning and therefore more
eﬃcient averaging of anisotropic interactions. Nevertheless, the
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smaller the rotor, the more challenging is its ﬁlling. Relatively
low-salt concentrations are important to achieve eﬃcient
radiofrequency ﬁelds and therefore short pulse lengths. Indeed,
ionic conductivity can lead to sample heating by radiofrequency
irradiation29 although new generations of low heat conductivity
probes seem promising. Multidimensional NMR experiments
are time-consuming, so that the samples need to be stable for
several days at least. If the samples are not homogeneous, a
superposition of the diﬀerent conformations will lead to
inhomogeneous line broadening30 and therefore poorly
resolved resonances in the NMR spectra. Crystalline samples
that contain molecules with a unique well-deﬁned conformation
give high-resolution solid-state NMR spectra. Only few
examples in the literature show highly resolved spectra of
microcrystalline proteins that are uniformly labeled with stable
isotopes such as carbon-13, nitrogen-15, or deuterium. To the
best of our knowledge, NMR spectra of microcrystals of
proteins that form complexes with a peptide, another protein,
or a nucleic acid have not been reported so far. The only
examples of protein complexes investigated by solid-state NMR
methods are pellets of proteoliposomes of a scorpion toxin-
membrane protein in the presence of a potassium channel
analogue31 and pellets of the periplasmic disulﬁde-donor
enzyme DsbA that is covalently bound to its oxidizing agent
DsbB.27 We consider that these pellets are not crystalline on
the micrometer scale. The highly resolved carbon-13 and
nitrogen-15 CPMAS NMR spectra reveal a homogeneous
sample, whereas the pellets stem from a centrifugation process
rather than a classical crystallization process.
This article presents the development and optimization of
several protein microcrystals preparation protocols: the Hen
Egg-White (HEW) lysozyme (129 residues), the 89 residue
(long) construct of the C-terminal domain (LCter) of Human
centrin 2, and the complex between the C-terminal domain
(Cter) of Human centrin 2 (79 residues) and the P17-XPC
peptide (17 residues). The latter Cter HsCen2/P17-XPC
complex is a good model of an intermediate that plays a role in
the DNA nuclear excision repair process involving Human
centrin 2 and Xeroderma Pigmentosum group C (XPC) protein
with hHR23B.32 Slow internal dynamics in the Cter HsCen2/
P17-XPC complex (on micro- to millisecond time scales) was
studied in solution by relaxation methods based on two-spin
multiple-quantum coherences.33 The present work represents a
preliminary step toward a detailed study of the internal
dynamics of the complex by solid-state NMR spectroscopy.
Here, we describe robust protocols to prepare microcrystals of
protein−peptide complexes with dimensions in the range of a
few micrometers. The present protocol is designed to fulﬁll the
requirements of solid-state NMR but can also be used for other
spectroscopic and biophysical techniques.
■ EXPERIMENTAL PROCEDURES
The concentrations of the protein samples were evaluated with a
Nanodrop apparatus against the corresponding buﬀers. At 280 nm, the
molar extinction coeﬃcients were 37 970, 1490, 5500, 11369, and 10
377 M−1·cm−1 for HEW lysozyme, Cter HsCen2, P17-XPC, Cter
HsCen2/P17-XPC complex, and LCter HsCen2, respectively. All
extinction coeﬃcients were determined by the ProtParam analysis tool
of the ExPASy database, based on knowledge of the amino acid
composition of the proteins.34−37 They correspond to the molar
extinction coeﬃcients of the native proteins. The diﬀerences between
the native and denatured molar extinction coeﬃcients are small.
Cter HsCen2: Protein Expression and Puriﬁcation. The
recombinant protein Cter HsCen2 (Thr94-Tyr172) was overexpressed
in a BL21(D3)/pDIA17 Escherichia coli strain38 and puriﬁed as
described previously.39 For doubly labeled samples (13C and 15N), we
used 4 L of minimum medium (M9) containing 15NH4Cl (1 g·L
−1)
and 13C6-glucose (3 g·L
−1) as the sole source of nitrogen and carbon,
respectively, and supplemented with 75 μg·mL−1 of kanamycin and 30
μg·mL−1 of chloramphenicol. The bacteria were grown at 310 K (37
°C). The value of the optical density (OD) was intentionally allowed
to reach 1.5, while classical protocols stop at 0.5−0.8. This permits to
gain in mass but diminishes the ﬁtness of the bacteria. Besides, it
prevents healthy bacteria (grown at OD 0.5−0.8) from destroying the
expressed protein. The expression was induced with 0.2 mM
isopropyl-beta-D-thiogalactoside (IPTG), and growth was prolonged
overnight at 310 K. The protein was puriﬁed according to the
procedure previously described.40 The puriﬁcation yielded 18 mg per
liter of E.coli culture for the doubly labeled Cter HsCen2 protein,
which was lyophilized and stored at 193 K (−80 °C).
Preparation of the Cter HsCen2/P17-XPC Complex in
Solution. The lyophilized protein was dissolved in 20 mM Tris at
pH 6.5 and 7.5 at various concentrations (2, 2.5, and 3 mM). The
concentration of NaCl was varied between 100 and 400 mM and
CaCl2 between 3 and 10 mM. The P17-XPC peptide Ac-
NWKLLAKGLLIRERLKR-NH2 (95% purity) was purchased from
GeneCust (Dudelange, Luxembourg). All new batches were dissolved
in Milli-Q water and lyophilized before use. Stock solutions were
prepared in Milli-Q water at diﬀerent concentrations (2−6 mM) and
stored at 193 K. Complex solutions with diﬀerent molar protein/
peptide ratios 1:1, 1:1.2, and 1:2 were obtained by mixing adequate
volumes of protein and peptide stock solutions. The pH of the
complex solutions was adjusted to 4.
The choice of the Tris buﬀer may seem questionable as its eﬀective
pH lays in the range of 7 to 9, while the isoelectric point is estimated
to 4.6 for the Cter HsCen2 domain and to 5.2 for the Cter HsCen2/
P17-XPC complex.37 The pH of the solution dropped to 4.8 upon the
addition of the lyophilized protein to 20 mM Tris at pH 7.5, but
microcrystals of the 1:2 complex were still obtained. Actually, the
initial pH of the protein can vary in the 4−8 range without impeding
crystallogenesis as it is adjusted to 4 before adding the precipitating
agent.
High-Throughput Crystallization. Initial crystallization screen-
ings were carried out taking advantage of the high-throughput
crystallization facility at the EMBL in Grenoble. The complex was
screened at three diﬀerent Cter HsCen2 concentrations (3, 6, and 12
mg·mL−1) against 576 crystallization cocktails (plates 1 and 6 from
Qiagen Nextal and plates 2, 3, 4, and 8 of Hampton Research). The
molar protein/peptide ratio was 1:2. The following three conditions
gave crystals at 293 K (20 °C): (a) protein concentration of 12
mg·mL−1, 0.5 M ammonium sulfate, 0.1 M HEPES at pH 7.5, and 30%
v/v MPD, (b) protein concentration of 6 mg·mL−1, 0.8 M sodium/
potassium phosphate at pH 8.2, 32 mM sodium dihydrogen phosphate
monohydrate, and 77 mM dipotassium hydrogen phosphate, and (c)
protein concentration of 6 mg·mL−1, 1.0 M sodium/potassium
phosphate at pH 8.2, 40 mM sodium dihydrogen phosphate
monohydrate, and 0.96 M dipotassium hydrogen phosphate. The
crystallization experiments were set up with a Cartesian PixSys 4200
crystallization robot (Genomic Solutions, UK) using Greiner Crystal
Quick plates (ﬂat bottom, untreated). The imaging system is a
RoboDesign Minstrel III (Rigaku Msc, UK) at 293 K and a
Formulatrix RockImager (Formulatrix, Inc., USA) at 277 K. Protocols
are described in the literature.41
Low-Salt Screening Conditions. High-throughput screening
resulted only in high-salt conditions that are not suitable for solid-
state NMR experiments. Therefore, further screening with Stura type
precipitating agents was performed on triplets of 2 μL volumes of
complex at diﬀerent concentrations and of precipitating agent by the
sitting-drop vapor-diﬀusion method. The solutions were either
purchased from Molecular Dimensions (Suﬀolk UK) or homemade.
In the latter case, the PEG was ﬁltered, and buﬀer solutions containing
0.05% NaN3 were ﬁltered through a 0.2 μm ﬁlter. The boxes were
prepared at room temperature, while the complex solutions were kept
on ice. Two precipitating agents permitted us to obtain microcrystals:
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(1) 46% v/v PEG 400 in citrate buﬀer at pH 5.5 and (2) 42% v/v PEG
600 in 0.2 M imidazole malate at pH 5.5. Crystals appeared within 24
h when the boxes were stored at 277 K and after 3 days at 290 K only
for a molar protein/peptide ratio of 1:2. Control experiments with the
buﬀer alone or the protein alone did not lead to any crystals. Although
dyeing the microcrystals with methylene blue was not conclusive, the
plate-like microcrystals of the complex gave X-ray diﬀraction patterns
with a resolution of 1.7 Å. After dissolving the microcrystals with 6 M
guanidinium hydrochloride, SDS PAGE gel electrophoresis gave a
band at the same molecular mass as the complex solution. To test their
stability, the microcrystals were stored at 310 K for 48 h. The integrity
of the microcrystals and possible changes in their morphology were
monitored qualitatively with a visible-light microscope. We therefore
chose 42% v/v PEG 600 in 0.2 M imidazole malate at pH 5.5 since no
morphological modiﬁcations were observed.
Precipitates of the Cter HsCen2/P17-XPC Complex. A
solution of the Cter HsCen2/P17-XPC complex was prepared as
described above using a molar ratio of 1:2 of Cter HsCen2 (28
mg·mL−1, 3 mM) in 20 mM Tris at pH 7.5, 400 mM NaCl, and 10
mM CaCl2 with P17-XPC peptide (13 mg·mL
−1, 6 mM) in Milli-Q
water. Microcrystals were obtained either by the vapor-diﬀusion
method or by the batch method by mixing equal volumes of the
complex solution with the commercial Stura 1D (Molecular
Dimensions, Suﬀolk UK) precipitating agent solution (42% v/v PEG
600, 0.2 M imidazole malate at pH 5.5) and covered with paraﬃn oil
(Hampton Research Corporation, HR3-411, USA) to prevent
evaporation. Volumes from 2 to 30 μL were tested using 24 well
plates. For the batch method, the reservoir was left empty. Precipitates
were obtained by the same procedure except using a molar ratio of 1:1
Cter HsCen2/P17-XPC solution and the same precipitating agent
conditions. Precipitates appeared at 277 K after one week.
Microcrystals for Solid-State NMR. HEW Lysozyme. Two stock
solutions of 37 and 70 mg·mL−1 were prepared in 100 mM sodium
acetate at pH 4.5. Duplicate drops of 4 to 40 μL with increments of 4
μL were deposited on a sitting-drop 24 wells plate for solutions of 37
and 70 mg·mL−1. The precipitating agent was composed of 33% w/v
PEG 2k, 6 mM trisodium citrate, and 100 mM sodium acetate at pH
4.5 and was added only to the reservoir (700 μL) and not to the drop
containing the protein. The boxes were prepared and stored in a cold
room at 277 K. Crystals obtained by the sitting-drop vapor-diﬀusion
method had average dimensions of 20 × 20 × 20 μm (see Figure 1a).
Drops with small volumes started to nucleate after 2 days. The
nucleation was allowed to continue for 60 days. A total volume of 288
μL of an aqueous suspension of lysozyme microcrystals was obtained
by collecting drops of 2 and 4 μL. The microcrystals were centrifuged
and the supernatant was discarded. The crystallization yield was
estimated by (1) measuring the absorbance at 280 nm of the
supernatant solution and comparing the obtained concentration of
noncrystallized protein to that of the stock solution and (2) dissolving
a small quantity of microcrystals with 6 M guanidinium hydrochloride
and measuring the absorbance of the solution at 280 nm. The yields
obtained by these two methods were 79 and 86%, respectively. The
lysozyme microcrystals were then centrifuged in a 4 mm ZrO2 rotor
with aliquots of 10 μL at 8500 rpm for 15 min at 277 K. The rotor was
stored at 277 K without sealing the cap. The mass of microcrystalline
lysozyme was estimated to be about 50 mg in the rotor. All MAS
rotors used in this work were made of zirconium dioxide and
purchased from the same provider (Cortecnet, France).
Cter HsCen2/P17-XPC Protein−Peptide Complex. The precipitat-
ing agent was composed of 42% v/v PEG 600 in 0.2 M imidazole
malate at pH 5.5. A crystalline mixture of a majority of urchin-like
crystals and a minority of plate-like crystals was obtained from a stock
solution of the protein complex by the sitting-drop vapor-diﬀusion
method at 277 K using 1 to 20 μL of the stock solution as described in
the Low-Salt Screening Conditions section. Urchin-like crystals
appeared after 24 h and did not evolve after 2 days. A total volume
of 678 μL of a suspension of microcrystals was collected. The
crystallization yield was estimated to be between 50−80% as
determined for the lysozyme microcrystals. Subsequently, about 19
mg of microcrystals were used to ﬁll both 1.3 and 2.5 mm rotors. The
ﬁlling of the small diameter MAS rotors was assisted by ultra-
centrifugation with home-built adaptors.42
Figure 1. (a) Crystals of Hen Egg-White (HEW) lysozyme obtained by depositing 100 μL of the mother solution (100 mg·mL−1 in 100 mM sodium
acetate at pH 4.5) on a watch lens stored in a Petri dish containing 7.5 mL of a precipitating agent composed of 33% w/v PEG 2k, 6 mM trisodium
citrate, and 100 mM sodium acetate at pH 4.5. (b) Plate-like crystals of Cter HsCen2/P17-XPC complex (molar ratio protein/peptide 1:2, 34
mg·mL−1 in 20 mM Tris at pH 7.5, 400 mM NaCl, 10 mM CaCl2) obtained by the batch method using 150 μL of mother solution, 150 μL of
precipitating agent (42% v/v PEG 600 in 0.2 M imidazole malate at pH 5.5) and 50 μL of paraﬃn oil to prevent evaporation. (c) Urchin-like crystals
of Cter HsCen2/P17-XPC complex obtained by vapor diﬀusion of 4 μL drops mother solution and 4 μL of precipitating agent in a reservoir
containing 700 μL of precipitating agent. (d) Mixture of urchin-like and plate-like crystals of Cter HsCen2/P17-XPC complex obtained by the vapor-
diﬀusion method using volumes of 20 μL.
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The plate-like crystals were obtained by the batch method by mixing
equal volumes (2−50 μL) of stock complex solution and precipitating
agent on a cell-culture plate with 96 wells. The box was refrigerated at
277 K. Plate-like crystals appeared after one day and the crystallization
lasted 3 days. A total volume of 1066 μL was collected. The
crystallization yields are similar to those observed in the case of urchin-
like crystals. Finally, we obtained about 25 mg of plate-like crystals,
which were partly used to ﬁll a 2.5 mm MAS rotor. The rest of the
aqueous microcrystalline suspension was stored at 277 K for several
months and turned to a white powder that was used to ﬁll a 1.3 mm
MAS rotor as described above.
LCter HsCen2 (M84-Y172). The protein was obtained as a proteolysis
product after overexpression of the integral Human centrin 2 as
described previously.39,40 Two stock solutions of LCter HsCen2 with
ﬁnal concentrations of 1.5 and 3 mM were prepared and stored at 277
K. Crystallization conditions were tested using the sitting-drop vapor-
diﬀusion method described above on 24-well plates containing
doublets of 2 μL drops of the protein solution. For each protein
concentration, two boxes were prepared at room temperature and
stored at 277 and 290 K. After 14 days, urchin-like crystals and ﬁne
needles appeared with concentrations of PEG 600 of 15, 24, and 42%
v/v at 290 K.
Collection of Microcrystals for Solid-State NMR. Collecting
microcrystals requires washing every single well with appropriate
precipitating agents. This is a tedious and time-consuming task. In fact,
the microcrystals tend to stick on the surface of the well and a thin cat
moustache is used to displace them from the surface of the well by
manipulating under binoculars. These manipulations were repeated
three times in order to gather as many crystals as possible. The
microcrystals are then pipetted carefully using pipet tips cut at the end
with a scalpel. Fast pipetting can trigger the precipitation of the
protein. Therefore, the scaling-up of the crystallogenesis was
performed in order to minimize losses in time, quality, and quantity
of the crystals.
Scaling-up Production of Microcrystals. For the sitting-drop
vapor-diﬀusion method, the sitting-drop well was replaced by a watch
glass and the reservoir well by a Petri box. This permitted to scale-up
the preparation to 200 μL of protein or complex solution. Bigger
stock-solution volumes (20, 50, 100, and 400 μL) were undertaken
with 9-well glass plates (Hampton Research Corporation, USA)
immobilized by polystyrene and placed into a Sandwich box (from the
same provider) containing 25 mL of precipitating agent. Boxes were
stored at 277, 290, or 305 K. Microcrystals appeared only in the case of
lysozyme (37 and 100 mg·mL−1) using drops of 100 and 200 μL on a
watch glass after 24 h at 305 K. The watch glass was placed inside a
plastic box containing 7.5 mL of precipitating agent and covered with a
Petri dish lid but not sealed. In the case of the highly concentrated
lysozyme solution, crystals appeared after 4 days, whereas the crystals
from the low concentrated lysozyme solution appeared only after 6
days. It is noteworthy that no precipitating agent needed to be added
to the HEW lysozyme drops, thus conﬁrming the very low-salt
conditions of HEW lysozyme crystallogenesis even for larger volumes.
On the contrary, a precipitating agent was added to the Cter HsCen2/
P17-XPC complex. Drops containing a mixture of urchin- and plate-
like microcrystals as well as drops composed of only plate-like
microcrystals of Cter HsCen2/P17-XPC complex could be obtained in
larger volumes (50 μL) using 1 mL pipet tips that were ﬂame-sealed
and cooled. Both the complex solution and precipitating agent (50 μL
of 42% v/v PEG 600 in 0.2 M imidazole malate at pH 5.5) were added
to the drop. In order to mimic the vapor-diﬀusion drop-reservoir
ensemble, the sealed pipet tip was plunged inside a 20 mL Falcon or
hemolyse tube containing 2 mL of precipitating agent at 277 K for four
days (see Figure 2).
For the batch method, either sealed pipet tips or microtubes
(Eppendorf type) were used and only tested for the Cter HsCen2/
P17-XPC complex crystallization. The sealed pipet tips stored at 277
and 290 K resulted in plate-like crystals, which could not be removed
from the pipet-tip surface. In the case of microtubes, plate-like crystals
were obtained after several days at 277 K. Microcrystallization can be
accelerated by seeding with microcrystals previously obtained from
screening low-salt conditions and crushing them inside the microtube.
The plate-like crystals appeared after 24 h at 277 K and settled by
gravitation.
Solid-State NMR Spectroscopy. Cross-polarization magic-angle
spinning (CPMAS) spectra of carbon-13 shown in Figure 3a,d,e were
obtained on a Bruker Avance III 400 MHz wide-bore spectrometer
equipped with a 4 mm double-resonance probe at a spinning
frequency of 10 kHz for the HEW lysozyme sample and with a 2.5
mm double-resonance probe at a spinning frequency of 10 kHz for the
Cter HsCen2/P17-XPC complex. The CPMAS spectra of Figure 3b,c
were recorded at spinning frequencies of 22.4 and 40 kHz,
respectively, on a Bruker Avance III 900 MHz standard-bore
spectrometer equipped with a 1.3 mm double-resonance probe. No
apodization was applied prior to Fourier transform. The experiments
were carried out at temperatures of 263 K (−10 °C), according to the
thermocouple, for the HEW lysozyme sample and at 277 K for the
Cter HsCen2/P17-XPC complex.
Cross-polarization used either square or ramped pulses at the n =
±1 Hartmann−Hahn43 conditions. The contact time was set to
optimize the transfer across all regions of the spectra. Either SPINAL
6444 or PISSARRO45,46 proton decoupling schemes were applied
during signal acquisition. A pulse length of 1.1τrot, where τrot is the
rotor period, was used for PISSARRO decoupling.
■ RESULTS AND DISCUSSION
Low-Salt Crystallization of HEW Lysozyme Suitable
for Solid-State NMR. Several preparations of microcrystals of
HEW lysozyme for solid-state NMR have been described in the
literature.47,48 All have high concentrations of salt and
precipitating agents. Here, we present a procedure to prepare
lysozyme microcrystals with low-salt concentrations, so as to
allow higher radiofrequency amplitudes, more eﬃcient
decoupling, and longer acquisition times. Indeed, the scaling-
up of the vapor-diﬀusion crystallization of HEW lysozyme in a
watch glass does not require the addition of any precipitating
agent to the protein solution. Only the protein buﬀer sodium
acetate is present in the microcrystals.
As described in the experimental part, regular crystals were
obtained as shown in Figure 1a. The crystals had average
dimensions of 20 × 20 × 20 μm. Figure 3a shows a carbon-13
CPMAS spectrum recorded in 2.5 h at natural abundance
exhibiting remarkable linewidths of 0.2 ppm (20 Hz) for
isolated methyl groups.
The preparation of very low-salt HEW lysozyme micro-
crystals without the addition of any precipitating agent to the
protein drop as described in the experimental section is very
attractive, but unfortunately, the method is not applicable to
our system of interest, the Cter HsCen2/P17-XPC complex.
Strategies and Screening of Crystallization Condi-
tions for Cter HsCen2 Constructs. The various precipitates
Figure 2. (a) Scheme of a sealed pipet cone containing complex
solution (light gray) and precipitating agent (dark gray) in a Falcon
tube, which was used as a scaling-up of the vapor-diﬀusion method.
(b) Microcrystals obtained directly inside the sealed pipet cone.
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of the Cter HsCen2/P17-XPC complex did not yield any
structured objects in the nanometer range as checked by
electron microscopy. It is therefore diﬃcult to draw conclusions
about the crystallinity of the precipitates of the complex
considering the dilution steps that could damage the fragile
crystals. The precipitates may be intrinsically unstructured. In
summary, electron microscopy does not allow the determi-
nation of the degree of crystallinity of precipitates and
nanocrystals of delicate biological systems like the Cter
HsCen2/P17-XPC complex.
X-ray powder diﬀraction has been used previously to
determine the degree of crystallinity of nanocrystals of
ubiquitin, lysozyme, ribonuclease A, streptavidin, and cyto-
chrome C.48 The nanocrystalline materials were produced by
rapid bulk crystallization, while scaling-up was performed
directly, by using a centrifugal evaporator, from the optimized
precipitation conditions previously obtained by initial screen-
ing. Unfortunately, this second approach is not applicable to
delicate systems such as protein complexes.
Figure 3. 13C CPMAS spectra of (a) natural abundance HEW lysozyme crystals packed in a 4 mm rotor spinning at 10 kHz at 9.4 T and of (b) plate-
like crystals of the complex U−13C, 15N-enriched Cter HsCen2/P17-XPC obtained by the batch method and stored at 277 K for 12 months after
collection. The plate-like crystals were packed in a 1.3 mm rotor spinning at 22.4 kHz at 21.1 T. (c) Sample freshly packed after collection in a 1.3
mm rotor spinning at 40 kHz at 21.1 T containing mainly urchin-like crystals of the U−13C, 15N-enriched Cter HsCen2/P17-XPC complex obtained
by vapor diﬀusion and recorded just after collection. (d) Sample packed in a 2.5 mm rotor spinning at 10 kHz at 9.4 T consisting of urchin-like
crystals obtained by vapor diﬀusion and recorded just after collection. (e) Sample packed in a 2.5 mm rotor spinning at 10 kHz at 9.4 T containing
mainly plate-like crystals of the U−13C, 15N-enriched Cter HsCen2/P17-XPC complex obtained by the batch method and recorded after collecting
the crystals.
Figure 4. Protocol for obtaining large-scale microcrystals and ﬁlling rotors for solid-state NMR.
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We therefore focused our eﬀorts on the production of the
protein−peptide complex microcrystals by adapting the single-
crystal protocol to large-scale production intended for solid-
state NMR applications. The diﬀerent steps and strategies
followed to obtain microcrystals of the Cter HsCen2/P17-XPC
complex in suﬃcient quantity for solid-state NMR are
illustrated in Figure 4. The same method can be applied to
other biological systems. The preparation of microcrystals of
the protein complex introduces additional optimization
parameters, as both the complex formation and crystallization
conditions need to be scaled-up in order to yield suﬃcient
quantities of homogeneous microcrystals to ﬁll NMR rotors.
As illustrated in Figure 4, the ﬁrst step is the screening of
crystallization conditions that are suitable for complex
formation at low-salt concentrations. Screening is done in
two stages. The ﬁrst screening uses a high-throughput robot for
crystallization with nanodrops allowing one to select eﬃcient
precipitating agents with suitable buﬀers to form microcrystals.
Selection of the appropriate condition is based on both
successful crystallization and a high concentration of micro-
crystals. This stands in contrast to crystallization protocols for
X-ray diﬀraction where single crystals are selected for the
regularity of their growth and easy handling. The primer
conditions are targeted as for the crystallization of single
crystals. This includes the control of the protein buﬀer and
peptide buﬀer solutions (concentrations, pH, temperature,
nature of the buﬀer, and order of mixture), as well as the molar
ratio of the partners in the complex, the nature of the
precipitating agent and its buﬀer solution and pH, the
temperature during crystal growth, and the method of
crystallization. The batch method has two major advantages
over the vapor-diﬀusion or dialysis methods: (i) the scaling-up
is easily implemented, and (ii) it allows an exact initial
supersaturation, in contrast to vapor-diﬀusion or dialysis
methods where the crystallization process starts from an
unsaturated state and evolves toward a supersaturated state.
Consequently, the supersaturation at which crystals are formed
is unknown in this case. Previous studies49 of the nucleation
behavior of lysozyme crystals have shown that the number of
crystals increases with increasing supersaturation and temper-
ature. However, the most relevant variable is pH since an
increase in the size and the number of crystals is observed with
decreasing pH. Results on lysozyme showed a change of 2
orders of magnitude in the number of crystals over a pH range
between 4.0 and 5.2. A so-called storage eﬀect (aging) of the
protein solution was also shown to inﬂuence the nucleation
process, therefore, the size and number of the crystals.50,51
Hence, the number of crystals increases while their size
decreases with storage time of the protein solution. This eﬀect
was ascribed to the presence of fungi that multiply in the stored
protein solution. The quality of the crystals is expected to
deteriorate, at least for X-ray diﬀraction studies using crystals
aged protein solutions. For the crystallization preparations
presented in this work, the protein, peptide, or complex
solutions were freshly prepared prior to crystallization.
Successful microcrystallization of the complex Cter HsCen2/
P17-XPC was observed for a 1:2 molar ratio of protein/peptide
Cter HsCen2/P17-XPC. Plate-like (Figure 1b) and urchin-like
Figure 5. Plate-like crystals of the complex Cter HsCen2/P17-XPC (molar ratio protein/peptide 1:2) obtained by the batch method. Each drop
contained 150 μL of mother solution (34 mg·mL−1 in 20 mM Tris at pH 7.5, 400 mM NaCl, 10 mM CaCl2) and 150 μL of precipitating agent (42%
v/v PEG 600 in 0.2 M imidazole malate pH 5.5) covered by 50 μL of paraﬃn oil to prevent evaporation. (a,b) Drops with only few single crystals
suitable for X-ray diﬀraction. (c) Drop with many crystals obtained by seeding with 2 μL of crushed plate-like crystals. (d,e) Drops with numerous
microcrystals obtained either by seeding with a cat moustache, which was in contact with plate-like crystals (d), or by simple mixing with a cat
moustache (e). The lower panels show zooms on crystals in the upper panels.
Figure 6. Needle-like crystals of LCter HsCen2 obtained by vapor diﬀusion using 2 μL mother solution (31 mg·mL−1 in 20 mM Tris at pH 7.5, 400
mM NaCl, 10 mM CaCl2) and 2 μL of precipitating agent (42% v/v PEG 600 in 0.2 M imidazole malate at pH 5.5) at 290 K after 2 weeks.
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microcrystals (Figure 1c) and mixtures thereof (Figure 1d)
were obtained (see Experimental Procedures). Our studies
showed that an excess of peptide was necessary. These
conditions were found by screening in the vicinity of the
conditions described in the literature for solution-state
NMR33,52 and crystallogenesis data on Human centrin 2
complexes.53,54 Note that both calcium-binding sites of Cter
HsCen2 must be saturated. In the case of partial saturation, a
mixture of diﬀerent forms is obtained, impeding complex
crystallization. Figure 5a shows a single crystal of the complex
perfectly adapted for an X-ray experiment. Figure 5b illustrates
a drop with single crystals not optimized for solid-state NMR
collection. One can induce/accelerate the crystallogenesis
either by microseeding with bits of crystal (Figure 5c), by
seeding with a cat moustache that was previously in contact
with crystals (Figure 5d), or by crushing the crystals (Figure
5e). Clearly, drops containing numerous microcrystals (Figure
5c−e) are more favorable to the collection stage.
Other types of microcrystals were obtained using a diﬀerent
construct of the C-terminal domain of HsCen2 (LCter HsCen2
M84-Y172) that contains 10 additional residues. The structure of
the LCter HsCen2 was previously determined by interpreting
interproton distances in NOESY experiments.39 The structure
shows that the additional 10 residues are located in the P17-
XPC peptide binding site. In this case, the crystallization was
easier because the same buﬀer and precipitating agent as for
Cter HsCen2 have been successfully used. Fine needles (see
Figure 6) appeared after 14 days of incubation at 290 K using
the sitting-drop vapor-diﬀusion method. These needles were
stable over several months at 290 K, but unfortunately,
attempts to collect them failed. Because of their strong aﬃnity
for the plastic well, they degraded during collection.
Furthermore, the needles appeared to have a low density and
were diﬃcult to centrifuge, and subsequently, the handling of
such needles for solid-state NMR was problematic.
Scaling-up Crystallogenesis for the Complex Cter
HsCen2/P17-XPC. Obviously, scaling-up the crystallization
volume is a challenge that needs to be overcome to produce
amounts of microcrystals that are suﬃcient to ﬁll a MAS rotor
for solid-state NMR. The quantity of protein microcrystals
required is on the order of 5−12 mg since a 1.3 mm MAS rotor
has a volume of 5 μL and a 2.5 mm rotor a volume of 12 μL.
The exact mass of microcrystals is diﬃcult to determine since
the samples contain substantial amounts of precipitating agent
and buﬀer. The use of a larger number of drops is not advisible,
not only from a manipulation point of view but also because the
integrity of the microcrystals might suﬀer during their
collection as described in the experimental part. Moreover,
the wells of the drops must be washed with precipitating agent
in order to collect as many microcrystals as possible. Adding 3-
fold volumes of precipitating agent to the collected drops
disrupts the subtle equilibrium between the concentrations of
the complex and the precipitating agent achieved at the
beginning of the batch method or at the end of nucleation in
the vapor-diﬀusion method. This addition can aﬀect the
evolution of stored microcrystals as will be illustrated later
with the NMR spectra. Therefore, several strategies have been
tested in order to minimize the number of manipulations of
microcrystals for vapor-diﬀusion and batch methods.
For the Cter HsCen2/P17-XPC complex, the best and most
straightforward approach was to crystallize directly inside a
microtube via the batch method after microseeding (see
Experimental Procedures) as shown in Figure 7. This technique
permits one to eliminate the supernatant and to directly obtain
a concentrated suspension of microcrystals without prior
treatment or addition of any other component, thus minimizing
the handling of these fragile microcrystals. Interestingly, the
plate-like crystals did not stick to the microtube.
Filling Small Diameter Rotors for ssNMR with Cter
HsCen2/P17-XPC Microcrystals. The last step of the sample
preparation protocol is the transfer of the microcrystals to solid-
state NMR sample holders, i.e., MAS rotors. The most
challenging is the ﬁlling of small outer diameter (1.3 and 2.5
mm) rotors. This requires homogeneous packing of the
microcrystals to achieve good ﬁlling factors and to allow
spinning at high frequencies (up to 65 kHz in 1.3 mm MAS
rotors). Indeed, the NMR signal is proportional to the number
of spins and therefore to the quantity of material. Böckmann et
al. described adaptors for packing MAS rotors with an
ultracentrifuge.42 We used ultracentrifugation in home-built
adaptors to ﬁll rotors with microcrystals of the Cter HsCen2/
P17-XPC complex.
We also developed a new method that uses an HPLC pump
to pack MAS rotors with microcrystals retained by a frit with
0.2 μm porosity (Figure 8). The empty rotor, a cylinder that
must be open on both sides, is placed inside an empty HPLC
column with an inner diameter that ﬁts the outer diameter of
the rotor. The suspension of microcrystals in the precipitating
agent is pumped through the assembly. This method is
successful when packing robust microcrystals of proteins such
as HEW lysozyme. Figure 8c shows MAS rotors packed with
HEW lysozyme microcrystals using the HPLC pump. This
method could also be applied to any other system in order to
ﬁll solid-state NMR rotors. For example, one could concentrate
ﬁbers or any kind of biopolymers if one utilizes a suitable
solvent to pack the rotor without solubilizing the objects of
interest.
Solid-State NMR Carbon-13 Spectra of Lysozyme and
Cter HsCen2/P17-XPC. Solid-state NMR spectroscopy is very
sensitive to the homogeneity of the sample. If a solid sample
contains diﬀerent species (i.e., aggregates, precipitates, or
diﬀerent crystalline forms), small variations in chemical shifts
will lead to broad resonances. As a consequence, site-speciﬁc
assignment will be challenging or impossible. Solid-state
carbon-13 CPMAS NMR spectra were recorded by cross-
Figure 7. (a) Plate-like crystals of the complex Cter HsCen2/P17-
XPC (molar ratio protein/peptide 1:2) obtained in a 1.5 mL
Eppendorf at 277 K 48 h after mixing 150 μL of mother solution
(34 mg·mL−1 in 20 mM Tris at pH 7.5, 400 mM NaCl, 10 mM CaCl2)
and 150 μL of precipitating agent (42% v/v PEG 600 in 0.2 M
imidazole malate pH 5.5) covered with 50 μL of paraﬃn oil to prevent
evaporation. The picture in panel b corresponds to a magniﬁcation of
10 of the square (white line) in panel a.
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polarization from protons to carbons to enhance the sensitivity
of the low-gamma nuclei, while spinning the sample at the
magic angle. Figure 3a,b exhibits remarkably narrow resonances
with linewidths of 0.3−0.5 ppm for microcrystals of (a) HEW
lysozyme and (b) Cter HsCen2/P17-XPC complex. Rotors
packed immediately after harvesting of the microcrystals
resulted in spectra with broad signals due very likely to the
superposition of contributions not only from microcrystals but
also from precipitates and aggregates. Microcrystals stored for
several months at 277 K yielded remarkably narrow linewidths
of 0.3 ppm (∼67 Hz) for isolated methyl groups in the complex
(Figure 3b), therefore, attesting for an evolution toward more
homogeneous samples with time. These results will be further
exploited for solid-state NMR assignment of the complex, and
followed by site-speciﬁc studies in the solid state.
■ CONCLUSIONS
The optimum conditions for the formation of microcrystals
that satisfy the requirements for solid-state NMR spectroscopy
depend on a variety of factors. Minimum manipulation of the
microcrystals and leaving of the samples for several months at
277 K allow one to obtain highly resolved NMR spectra.
Among the three systems investigated, the crystallization of the
Cter HsCen2/P17-XPC complex was the most challenging
because protein/peptide molar ratio, pH, temperature,
precipitating agent, and crystallization method all inﬂuence
the outcome. To our knowledge, this is the ﬁrst microcrystal-
line protein−peptide complex studied by solid-state NMR. We
have designed a device for ﬁlling MAS rotors with protein
microcrystals that uses basic HPLC equipment. The prepara-
tion protocols described in this work are not limited to solid-
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